Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14919273 | 1.00 | PNMT (0.33) | PNMT | |
| SCHEMBL5178366 | 0.81 | — | — | |
| SCHEMBL16992638 | 0.77 | — | — | |
| SCHEMBL101769 | 0.74 | — | — | |
| SCHEMBL577008 | 0.74 | ALDH1A1 (0.36) | PNMT | |
| SCHEMBL23802873 | 0.74 | ALDH1A1 (0.36) | PNMT | |
| SCHEMBL16924872 | 0.74 | ALDH1A1 (0.36) | PNMT | |
| SCHEMBL2453706 | 0.74 | — | — | |
| SCHEMBL6368791 | 0.74 | — | — | |
| SCHEMBL235448 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017043636-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE OF SAME | 大日本住友製薬株式会社 | 2017-03-16 | — | — | WO | disclosed |
| EP-2847191-B1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2016-06-15 | — | — | EP | disclosed |
| US-9133181-B2 | Substituted 6-(4-hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-20150133432-A1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | SANOFI (FR) | 2015-05-14 | — | — | US | disclosed |
| EP-2847191-A1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | SANOFI (FR) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013167403-A1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | SANOFI (FR) | 2013-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133432-A1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | MAP3K1, MAP3K6, MAP3K19 | PNMT 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.